Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832253 | 0.75 | MAOA (0.33) | KDM4EALDH1A1HSD17B10TDP1KDR | |
| SCHEMBL832914 | 0.72 | ELANE (0.39) | KDM4EALDH1A1CYP2A6HPGDMAPT | |
| SCHEMBL87603 | 0.70 | DNMT1 (0.42) | KDM4EALDH1A1HSD17B10TDP1DNMT1 | |
| SCHEMBL2461072 | 0.70 | KDM4E (0.43) | KDM4EGPR3ALDH1A1HSD17B10PARP1 | |
| SCHEMBL28262113 | 0.67 | KDM4E (0.39) | KDM4EGPR3ALDH1A1HSD17B10PARP1 | |
| SCHEMBL6434380 | 0.67 | MAPT (0.46) | KDM4EGPR3ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL378548 | 0.67 | KDM4E (0.39) | KDM4EGPR3ALDH1A1HSD17B10PARP1 | |
| SCHEMBL1478086 | 0.67 | KDM4E (0.39) | KDM4EGPR3ALDH1A1HSD17B10PARP1 | |
| SCHEMBL27619154 | 0.66 | KDM4E (0.38) | KDM4EGPR3ALDH1A1HSD17B10PARP1 | |
| SCHEMBL27619538 | 0.66 | KDM4E (0.38) | KDM4EGPR3ALDH1A1HSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-12 | — | — | US | disclosed |
| WO-2021086107-A1 | METHOD FOR DETERMINING REACTIVITY TO PARP INHIBITOR | (재)록원바이오융합연구재단 | 2021-05-06 | — | — | WO | disclosed |
| WO-2012151701-A1 | METHODS FOR THE TREATMENT AND DIAGNOSTIC OF PULMONARY ARTERIAL HYPERTENSION | UNIVERSITÉ LAVAL / VICE-RECTORAT À LA RECHERCHE ET À LA CRÉATION (CA) | 2012-11-15 | — | — | WO | disclosed |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | The Institute of Cancer Reseach | 2012-05-31 | — | — | US | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | KDM4E 872/4885GPR3 3187/4885ALDH1A1 349/4885 |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | MRE11, ERCC4, PARP2 | KDM4E 2630/4885GPR3 4014/4885ALDH1A1 729/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | KDM4E 2744/4885GPR3 3978/4885ALDH1A1 744/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | KDM4E 820/4885GPR3 3240/4885ALDH1A1 2811/4885 |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | KDM4E 2660/4885GPR3 4004/4885ALDH1A1 747/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | KDM4E 2630/4885GPR3 4014/4885ALDH1A1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.